Nucleic Acid Therapeutics CDMO Market - A Global and Regional Analysis: Focus on Product, Technology, and End User - Analysis and Forecast, 2021-2030
Market Report Coverage - Nucleic Acid Therapeutics CDMO
Market SegmentationProduct – Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, Other Services Chemical Synthesis – Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis Technology – Column-Based Method, Microarray-Based Method End User – Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories Regional SegmentationNorth America – U.S., Canada Europe – Germany, U.K., France, Italy, Spain, Rest-of-Europe Asia-Pacific – Japan, China, India, Australia, Rest-of-Asia-Pacific Rest-of-the-World Market Growth DriversAccelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products Reduction in Overall Manufacturing Cost at CDMOs Rising Approvals of Nucleic Acid Therapeutics Market ChallengesLack of Expertise in Nucleic Acid Manufacturing Supply Chain and Logistical Challenges Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids Market OpportunitiesIncreasing Outsourcing Trend Among Pharmaceutical Companies Accelerating Research and Development Along with Technology Growth in Developing Countries Key Companies Profiled
Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG, Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc., QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation
Key Questions Answered in this Report:What are the different types of nucleic acid therapies available in the global nucleic acid therapeutics CDMO market? What are the key development strategies implemented by the key players to stand out in this global nucleic acid therapeutics CDMO market? What are the manufacturing locations of the key companies within the global nucleic acid therapeutics CDMO market? What are the various manufacturing technologies within the global nucleic acid therapeutics CDMO market? How have the strategic collaborations among the key players provided a push to product development within the global nucleic acid therapeutics CDMO market? Which are the leading companies that are dominating the global nucleic acid therapeutics CDMO market? Based on the product type, which therapy in the global nucleic acid therapeutics CDMO market is anticipated to witness a massive rise in demand during the forecast period? How is each segment of the global nucleic acid therapeutics CDMO market expected to grow during the forecast period, and what revenue is expected to be generated by each of these segments by the end of 2030? Market Overview
The completion of human genome sequencing and the elucidation of the molecular pathways that are critical in the disease molecule interaction have offered an unprecedented opportunity and growth for the development of nucleic acid-based therapeutics. However, to keep with the manufacturing and development of such therapies, the pharmaceutical companies have established partnerships with the contract development and manufacturing company (CDMO) which are the viable alternatives to the in-house development of the drugs. Moreover, the success of the respective business model has also led these CDMOs to become an integral part of such pharmaceutical companies’ value chain.
The increasing willingness to outsource drug development to the CDMOs, and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic acid therapeutics CDMO.
In the past decade, there has been a vast increase in the amount of gene sequence information that has the potential to revolutionize the way diseases are categorized and treated. Traditional diagnoses, largely anatomical or descriptive in nature, are likely to be superseded by the molecular characterization of the disease. The fact that certain genes drive key disease processes will also enable the rational design of gene-specific therapeutics. Antisense oligonucleotides represent a technology that can play multiple roles in this process. Further, at present, there are 16 nucleic acid therapies approved by the FDA and EMA and many more in the pipeline implying the reliance and acceptance over the usage of such therapies in the market.
Within the research report, the market is segmented on the basis of product type, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of nucleic acid therapeutics CDMO market on the global level has created a buzz among companies to invest in the manufacturing of nucleic acid-based therapies. In the past five years (July 2017-July 2021), the nucleic acid therapeutics CDMO market witnessed approximately 31 notable key developments. These included one product launch, two regulatory and legal activities, three mergers and acquisitions, 24 synergistic developments (partnerships, collaborations, agreements, and business expansion activities).
On the basis of region, North America holds the largest share within the nucleic acid therapeutics CDMO manufacturing due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period of 2021-2030.
Market Segmentation
Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG, Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc., QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation
Key Questions Answered in this Report:
The completion of human genome sequencing and the elucidation of the molecular pathways that are critical in the disease molecule interaction have offered an unprecedented opportunity and growth for the development of nucleic acid-based therapeutics. However, to keep with the manufacturing and development of such therapies, the pharmaceutical companies have established partnerships with the contract development and manufacturing company (CDMO) which are the viable alternatives to the in-house development of the drugs. Moreover, the success of the respective business model has also led these CDMOs to become an integral part of such pharmaceutical companies’ value chain.
The increasing willingness to outsource drug development to the CDMOs, and the rising need for pharmaceuticals have resulted in the expansion of the global market for nucleic acid therapeutics CDMO.
In the past decade, there has been a vast increase in the amount of gene sequence information that has the potential to revolutionize the way diseases are categorized and treated. Traditional diagnoses, largely anatomical or descriptive in nature, are likely to be superseded by the molecular characterization of the disease. The fact that certain genes drive key disease processes will also enable the rational design of gene-specific therapeutics. Antisense oligonucleotides represent a technology that can play multiple roles in this process. Further, at present, there are 16 nucleic acid therapies approved by the FDA and EMA and many more in the pipeline implying the reliance and acceptance over the usage of such therapies in the market.
Within the research report, the market is segmented on the basis of product type, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the application of nucleic acid therapeutics CDMO market on the global level has created a buzz among companies to invest in the manufacturing of nucleic acid-based therapies. In the past five years (July 2017-July 2021), the nucleic acid therapeutics CDMO market witnessed approximately 31 notable key developments. These included one product launch, two regulatory and legal activities, three mergers and acquisitions, 24 synergistic developments (partnerships, collaborations, agreements, and business expansion activities).
On the basis of region, North America holds the largest share within the nucleic acid therapeutics CDMO manufacturing due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period of 2021-2030.
1 MARKETS
1.1 Industry Outlook
1.1.1 Global Nucleic Acid Therapeutics CDMO Market Overview
1.2 Product Definition
1.3 Global Nucleic Acid Therapeutics CDMO Market Footprint, ($ Million), 2020-2030
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti?Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA interference [RNAi] and short interfering RNAs [siRNAs]
1.6.3 MicroRNAs
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Market Dynamics
1.7.1 Market Drivers
1.7.1.1 Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products
1.7.1.2 Reduction in Overall Manufacturing Cost at CDMOs
1.7.1.3 Rising Approvals of Nucleic Acid Therapeutics
1.7.2 Restraints
1.7.2.1 Lack of Expertise in Nucleic Acid Manufacturing
1.7.2.2 Supply Chain and Logistical Challenges
1.7.2.3 Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids
1.7.3 Opportunities
1.7.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies
1.7.3.2 Accelerating Research and Development Along with Technology
1.7.3.3 Growth in Developing Countries
2 COMPETITIVE LANDSCAPE
2.1 New Offerings and Funding and Investments
2.2 Regulatory and Legal
2.3 Mergers and Acquisitions
2.4 Synergistic Activities
2.5 Market Share Analysis
2.6 Growth Share Analysis
3 CHEMICAL SYNTHESIS METHOD
3.1 Overview
3.1.1 Solid-Phase Oligonucleotide Synthesis
3.1.1.1 Advantages and Challenges of SPOS
3.1.1.2 Method
3.1.1.2.1 Deprotecting/Detritylation
3.1.1.2.2 Coupling
3.1.1.2.3 Oxidation/Sulfurization
3.1.1.2.4 Capping
3.1.1.3 Cleavage and Deprotection
3.1.1.4 Purification
3.1.2 Liquid-Phase Oligonucleotide Synthesis
3.1.2.1 Advantages and Challenges of LPOS
4 TECHNOLOGY
4.1 Overview
4.1.1 Column-Based Method
4.1.2 Microarray-Based Method
5 END-USER
5.1 Overview
5.1.1 Pharmaceutical Companies
5.1.2 Academic Research Institute
5.1.3 Diagnostic Laboratories
6 PRODUCTS
6.1 Global Nucleic Acid Therapeutics CDMO Market (by Product)
6.1.1 Standard Nucleic Acid
6.1.2 Micro-Scale Nucleic Acid
6.1.3 Large-Scale Nucleic Acid
6.1.4 Custom Nucleic Acid
6.1.5 Modified Nucleic Acid
6.1.6 Primers
6.1.7 Probes
6.1.8 Other Nucleic Acid
6.1.9 Other Services
7 REGIONS
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest-of-Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Australia
7.4.5 Rest-of-Asia-Pacific
7.5 Rest-of-the-World
8 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
8.1 Competitive Benchmarking
8.2 Agilent Technologies, Inc.
8.2.1 Company Overview
8.2.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.2.3 Financials
8.2.4 Key Insights About Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Ajinomoto Co. Inc.
8.3.1 Company Overview
8.3.2 Role of Ajinomoto Co. Inc. in Global Nucleic Acid Therapeutics CDMO Market
8.3.3 Financials
8.3.4 SWOT Analysis
8.4 Bachem Holding AG.
8.4.1 Company Overview
8.4.2 Role of Bachem Holding AG. in Global Nucleic Acid Therapeutics CDMO Market
8.4.3 SWOT Analysis
8.5 Biospring GmbH
8.5.1 Company Overview
8.5.2 Role of Biospring GmbH in Global Nucleic Acid Therapeutics CDMO Market
8.5.3 SWOT Analysis
8.6 Corden Pharma International
8.6.1 Company Overview
8.6.2 Role of Corden Pharma International in the Global Nucleic Acid Therapeutics CDMO Market
8.6.3 SWOT Analysis
8.7 Danaher Corporation
8.7.1 Company Overview
8.7.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
8.7.3 Financials
8.7.4 Key Insights About Financial Health of the Company
8.7.5 SWOT Analysis
8.8 Guangzhou Ruibo Biotechnology Co., Ltd.
8.8.1 Company Overview
8.8.2 Role of Guangzhou Ruibo Biotechnology Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.8.3 SWOT Analysis
8.9 KNC Laboratories Co., Ltd.
8.9.1 Company Overview
8.9.2 Role of KNC Laboratories Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.9.3 Financials
8.9.4 SWOT Analysis
8.1 LGC Limited
8.10.1 Company Overview
8.10.2 Role of LGC Limited in the Global Nucleic Acid Therapeutics CDMO Market
8.10.3 Financials
8.10.4 Key Insights About Financial Health of the Company
8.10.5 SWOT Analysis
8.11 Merck KGaA
8.11.1 Company Overview
8.11.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
8.11.3 Financials
8.11.4 Key Insights About Financial Health of the Company
8.11.5 SWOT Analysis
8.12 Nippon Shokubai Co., Ltd.
8.12.1 Company Overview
8.12.2 Role of Nippon Shokubai Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.12.3 Financials
8.12.4 Key Insights About Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Nitto Denko Avecia Inc.
8.13.1 Company Overview
8.13.2 Role of Nitto Denko Avecia Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.13.3 SWOT Analysis
8.14 QIAGEN N.V.
8.14.1 Company Overview
8.14.2 Role of QIAGEN N.V. in the Global Nucleic Acid Therapeutics CDMO Market
8.14.3 Financials
8.14.4 Key Insights About Financial Health of the Company
8.14.5 SWOT Analysis
8.15 ST Pharm Co Ltd
8.15.1 Company Overview
8.15.2 Role of ST Pharm Co Ltd in Global Nucleic Acid Therapeutics CDMO Market
8.16 Sumitomo Chemical Co., Ltd.
8.16.1 Company Overview
8.16.2 Role of Sumitomo Chemical Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.16.3 Financials
8.16.4 Key Insights About Financial Health of the Company
8.16.5 SWOT Analysis
8.17 Syngene International Limited
8.17.1 Company Overview
8.17.2 Role of Syngene International Limited in the Global Nucleic Acid Therapeutics CDMO Market
8.17.3 Financials
8.17.4 Key Insights About Financial Health of the Company
8.17.5 SWOT Analysis
8.18 Thermo Fisher Scientific Inc.
8.18.1 Company Overview
8.18.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.18.3 Financials
8.18.4 Key Insights About Financial Health of the Company
8.18.5 SWOT Analysis
8.19 Wuxi AppTec
8.19.1 Company Overview
8.19.2 Role of Wuxi AppTec in the Global Nucleic Acid Therapeutics CDMO Market
8.19.3 Financials
8.19.4 Key Insights About Financial Health of the Company
8.19.5 SWOT Analysis
8.2 Yamasa Corporation
8.20.1 Company Overview
8.20.2 Role of Yamasa Corporation in the Global Nucleic Acid Therapeutics CDMO Market
8.20.3 SWOT Analysis
1.1 Industry Outlook
1.1.1 Global Nucleic Acid Therapeutics CDMO Market Overview
1.2 Product Definition
1.3 Global Nucleic Acid Therapeutics CDMO Market Footprint, ($ Million), 2020-2030
1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
1.5 Significant Usage of Nucleic Acid in Therapeutics
1.6 Types of Nucleic Acid Synthesized for Therapeutics
1.6.1 Anti?Sense Oligonucleotides (ASOs) and DNA Aptamers
1.6.2 RNA interference [RNAi] and short interfering RNAs [siRNAs]
1.6.3 MicroRNAs
1.6.4 RNA Aptamers and RNA Decoys
1.6.5 Ribozymes
1.6.6 Circular RNAs
1.7 Market Dynamics
1.7.1 Market Drivers
1.7.1.1 Accelerating Shift of the Pharmaceutical Market Toward Innovative Biologic and Cell and Gene Therapy Products
1.7.1.2 Reduction in Overall Manufacturing Cost at CDMOs
1.7.1.3 Rising Approvals of Nucleic Acid Therapeutics
1.7.2 Restraints
1.7.2.1 Lack of Expertise in Nucleic Acid Manufacturing
1.7.2.2 Supply Chain and Logistical Challenges
1.7.2.3 Difficult Therapeutic Classification Due to Wide Variety of Nucleic Acids
1.7.3 Opportunities
1.7.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies
1.7.3.2 Accelerating Research and Development Along with Technology
1.7.3.3 Growth in Developing Countries
2 COMPETITIVE LANDSCAPE
2.1 New Offerings and Funding and Investments
2.2 Regulatory and Legal
2.3 Mergers and Acquisitions
2.4 Synergistic Activities
2.5 Market Share Analysis
2.6 Growth Share Analysis
3 CHEMICAL SYNTHESIS METHOD
3.1 Overview
3.1.1 Solid-Phase Oligonucleotide Synthesis
3.1.1.1 Advantages and Challenges of SPOS
3.1.1.2 Method
3.1.1.2.1 Deprotecting/Detritylation
3.1.1.2.2 Coupling
3.1.1.2.3 Oxidation/Sulfurization
3.1.1.2.4 Capping
3.1.1.3 Cleavage and Deprotection
3.1.1.4 Purification
3.1.2 Liquid-Phase Oligonucleotide Synthesis
3.1.2.1 Advantages and Challenges of LPOS
4 TECHNOLOGY
4.1 Overview
4.1.1 Column-Based Method
4.1.2 Microarray-Based Method
5 END-USER
5.1 Overview
5.1.1 Pharmaceutical Companies
5.1.2 Academic Research Institute
5.1.3 Diagnostic Laboratories
6 PRODUCTS
6.1 Global Nucleic Acid Therapeutics CDMO Market (by Product)
6.1.1 Standard Nucleic Acid
6.1.2 Micro-Scale Nucleic Acid
6.1.3 Large-Scale Nucleic Acid
6.1.4 Custom Nucleic Acid
6.1.5 Modified Nucleic Acid
6.1.6 Primers
6.1.7 Probes
6.1.8 Other Nucleic Acid
6.1.9 Other Services
7 REGIONS
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest-of-Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Australia
7.4.5 Rest-of-Asia-Pacific
7.5 Rest-of-the-World
8 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
8.1 Competitive Benchmarking
8.2 Agilent Technologies, Inc.
8.2.1 Company Overview
8.2.2 Role of Agilent Technologies, Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.2.3 Financials
8.2.4 Key Insights About Financial Health of the Company
8.2.5 SWOT Analysis
8.3 Ajinomoto Co. Inc.
8.3.1 Company Overview
8.3.2 Role of Ajinomoto Co. Inc. in Global Nucleic Acid Therapeutics CDMO Market
8.3.3 Financials
8.3.4 SWOT Analysis
8.4 Bachem Holding AG.
8.4.1 Company Overview
8.4.2 Role of Bachem Holding AG. in Global Nucleic Acid Therapeutics CDMO Market
8.4.3 SWOT Analysis
8.5 Biospring GmbH
8.5.1 Company Overview
8.5.2 Role of Biospring GmbH in Global Nucleic Acid Therapeutics CDMO Market
8.5.3 SWOT Analysis
8.6 Corden Pharma International
8.6.1 Company Overview
8.6.2 Role of Corden Pharma International in the Global Nucleic Acid Therapeutics CDMO Market
8.6.3 SWOT Analysis
8.7 Danaher Corporation
8.7.1 Company Overview
8.7.2 Role of Danaher Corporation in the Global Nucleic Acid Therapeutics CDMO Market
8.7.3 Financials
8.7.4 Key Insights About Financial Health of the Company
8.7.5 SWOT Analysis
8.8 Guangzhou Ruibo Biotechnology Co., Ltd.
8.8.1 Company Overview
8.8.2 Role of Guangzhou Ruibo Biotechnology Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.8.3 SWOT Analysis
8.9 KNC Laboratories Co., Ltd.
8.9.1 Company Overview
8.9.2 Role of KNC Laboratories Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.9.3 Financials
8.9.4 SWOT Analysis
8.1 LGC Limited
8.10.1 Company Overview
8.10.2 Role of LGC Limited in the Global Nucleic Acid Therapeutics CDMO Market
8.10.3 Financials
8.10.4 Key Insights About Financial Health of the Company
8.10.5 SWOT Analysis
8.11 Merck KGaA
8.11.1 Company Overview
8.11.2 Role of Merck KGaA in the Global Nucleic Acid Therapeutics CDMO Market
8.11.3 Financials
8.11.4 Key Insights About Financial Health of the Company
8.11.5 SWOT Analysis
8.12 Nippon Shokubai Co., Ltd.
8.12.1 Company Overview
8.12.2 Role of Nippon Shokubai Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.12.3 Financials
8.12.4 Key Insights About Financial Health of the Company
8.12.5 SWOT Analysis
8.13 Nitto Denko Avecia Inc.
8.13.1 Company Overview
8.13.2 Role of Nitto Denko Avecia Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.13.3 SWOT Analysis
8.14 QIAGEN N.V.
8.14.1 Company Overview
8.14.2 Role of QIAGEN N.V. in the Global Nucleic Acid Therapeutics CDMO Market
8.14.3 Financials
8.14.4 Key Insights About Financial Health of the Company
8.14.5 SWOT Analysis
8.15 ST Pharm Co Ltd
8.15.1 Company Overview
8.15.2 Role of ST Pharm Co Ltd in Global Nucleic Acid Therapeutics CDMO Market
8.16 Sumitomo Chemical Co., Ltd.
8.16.1 Company Overview
8.16.2 Role of Sumitomo Chemical Co., Ltd. in the Global Nucleic Acid Therapeutics CDMO Market
8.16.3 Financials
8.16.4 Key Insights About Financial Health of the Company
8.16.5 SWOT Analysis
8.17 Syngene International Limited
8.17.1 Company Overview
8.17.2 Role of Syngene International Limited in the Global Nucleic Acid Therapeutics CDMO Market
8.17.3 Financials
8.17.4 Key Insights About Financial Health of the Company
8.17.5 SWOT Analysis
8.18 Thermo Fisher Scientific Inc.
8.18.1 Company Overview
8.18.2 Role of Thermo Fisher Scientific Inc. in the Global Nucleic Acid Therapeutics CDMO Market
8.18.3 Financials
8.18.4 Key Insights About Financial Health of the Company
8.18.5 SWOT Analysis
8.19 Wuxi AppTec
8.19.1 Company Overview
8.19.2 Role of Wuxi AppTec in the Global Nucleic Acid Therapeutics CDMO Market
8.19.3 Financials
8.19.4 Key Insights About Financial Health of the Company
8.19.5 SWOT Analysis
8.2 Yamasa Corporation
8.20.1 Company Overview
8.20.2 Role of Yamasa Corporation in the Global Nucleic Acid Therapeutics CDMO Market
8.20.3 SWOT Analysis
LIST OF FIGURES
Figure 1: Global Nucleic Acid Therapeutics CDMO Market, Realistic and Optimistic Scenario, $Million
Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
Figure 3: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 4: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019-2020
Figure 5: Global Nucleic Acid Therapeutics CDMO Market Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Global Nucleic Acid Therapeutics CDMO Market, $Million, 2020-2030
Figure 8: Optimistic View of Global Nucleic Acid Therapeutics CDMO Market, $Million
Figure 9: Overview of CRO and CDMO Services
Figure 10: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
Figure 11: Deal Value of Mergers and Acquisitions Involving Cell and Gene Therapies (2016-2019)
Figure 12: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 13: Share of Mergers and Acquisitions (by Company), 2017-2021
Figure 14: Share of Synergistic Activities (by Company), 2017-2021
Figure 15: Market Share Analysis for Global Nucleic Acid Therapeutics CDMO Market, 2020
Figure 16: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company),2019- 2020
Figure 17: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
Figure 18: Share of Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), 2020 and 2030
Figure 19: Solid-Phase Oligonucleotide Synthesis Market Size and Forecast
Figure 20: Liquid-Phase Oligonucleotide Synthesis Market Size and Forecast
Figure 21: Share of Global Nucleic Acid Therapeutics CDMO Market (by Technology), 2020 and 2030
Figure 22: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), 2020-2030
Figure 23: Global Nucleic Acid Therapeutics CDMO Market (by Microarray-Based Method), 2020-2030
Figure 24: Global Nucleic Acid Therapeutics CDMO Market, by End User, 2020 and 2030 ($Million)
Figure 25: Global Nucleic Acid Therapeutics CDMO Market, by Pharmaceutical and Biotechnology Companies
Figure 26: Global Nucleic Acid Therapeutics CDMO Market, by Academic Research Institutes
Figure 27: Global Nucleic Acid Therapeutics CDMO Market, by Diagnostic Laboratories
Figure 28: Global Nucleic Acid Therapeutics CDMO Market (by Product)
Figure 29: Share of Global Nucleic Acid Therapeutics CDMO Market (by Product), 2020 and 2030 ($Million)
Figure 30: Global Nucleic Acid Therapeutics CDMO Market, by Standard Nucleic Acid
Figure 31: Global Nucleic Acid Therapeutics CDMO Market, by Micro-Scale Nucleic Acid
Figure 32: Global Nucleic Acid Therapeutics CDMO Market, by Large-Scale Nucleic Acid Market
Figure 33: Global Nucleic Acid Therapeutics CDMO Market, by Custom Nucleic Acid
Figure 34: Global Nucleic Acid Therapeutics CDMO Market, by Modified Nucleic Acid
Figure 35: Global Nucleic Acid Therapeutics CDMO Market Primer Market, by Primers
Figure 36: Global Nucleic Acid Therapeutics CDMO Market, by Primer
Figure 37: Global Nucleic Acid Therapeutics CDMO Market, by Others NA
Figure 38: Global Nucleic Acid Therapeutics CDMO Market, Other Services
Figure 39: Global Nucleic Acid Therapeutics CDMO Market (by Region), Million Units, 2020-2030
Figure 40: Share of North America Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
Figure 41: North America: Market Dynamics
Figure 42: U.S. Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
Figure 43: Canada Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
Figure 44: Share of Europe Nucleic Acid Therapeutics CDMO Market (by Country), 2020-2030, $Million
Figure 45: Europe: Market Dynamics
Figure 46: Germany Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 47: U.K. Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 48: France Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 49: Italy Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 50: Spain Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 51: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 52: APAC: Market Dynamics
Figure 53: Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
Figure 54: China Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 55: India Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 56: Japan Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 57: Australia Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 58: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 59: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 60: Shares of Key Company Profiles
Figure 61: Agilent Technologies, Inc.: Product Portfolio
Figure 62: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 63: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 64: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 65: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 66: Agilent Technologies, Inc.: SWOT Analysis
Figure 67: Ajinomoto Co. Inc,: Overall Product Portfolio
Figure 68: Ajinomoto Co., Inc.: Overall Financials, 2017-2019
Figure 69: Ajinomoto Co., Inc.: Revenue (by Segment), 2017-2019
Figure 70: Ajinomoto Co., Inc.: SWOT Analysis
Figure 71: Bachem Holding AG.: Overall Product Portfolio
Figure 72: Bachem Holding AG.: SWOT Analysis
Figure 73: Biospring GmbH: Overall Product Portfolio
Figure 74: Biospring GmbH: SWOT Analysis
Figure 75: Corden Pharma International: Overall Product Portfolio
Figure 76: Corden Pharma International: SWOT Analysis
Figure 77: Danaher Corporation: Product Portfolio
Figure 78: Danaher Corporation: Overall Financials, 2018-2020
Figure 79: Danaher Corporation: Revenue (by Segment), 2018-2020
Figure 80: Danaher Corporation: Revenue (by Region), 2018-2020
Figure 81: Danaher Corporation: R&D Expenditure, 2018-2020
Figure 82: Danaher Corporation: SWOT Analysis
Figure 83: Guangzhou Ruibo Biotechnology Co., Ltd.: Product Portfolio
Figure 84: Guangzhou Ruibo Biotechnology Co., Ltd: SWOT Analysis
Figure 85: KNC Laboratories Co., Ltd.: Overall Product Portfolio
Figure 86: KNC Laboratories Co., Ltd.: Overall Financials, 2018-2020
Figure 87: KNC Laboratories Co., Ltd.: SWOT Analysis
Figure 88: LGC Limited: Overall Product Portfolio
Figure 89: LGC Limited: Overall Financials, 2018-2020
Figure 90: LGC Limited: Revenue (by Segment), 2018-2020
Figure 91: LGC Limited: R&D Expenditure, 2018-2020
Figure 92: LGC Limited: SWOT Analysis
Figure 93: Merck KGaA: Product Portfolio
Figure 94: Merck KGaA: Overall Financials, 2018-2020
Figure 95: Merck KGaA: Revenue (by Segment), 2018-2020
Figure 96: Merck KGaA: Revenue (by Region), 2018-2020
Figure 97: Merck KGaA: R&D Expenditure, 2018-2020
Figure 98: Merck KGaA: SWOT Analysis
Figure 99: Nippon Shokubai Co., Ltd.: Overall Financials, 2018-2020
Figure 100: Nippon Shokubai Co., Ltd: Revenue (by Segment), 2018-2020
Figure 101: Nippon Shokubai Co., Ltd: R&D Expenditure, 2018-2020
Figure 102: Nippon Shokubai Co., Ltd: SWOT Analysis
Figure 103: Nitto Denko Avecia Inc.: Product Portfolio
Figure 104: Nitto Denko Avecia Inc.: SWOT Analysis
Figure 105: QIAGEN N.V.: Product Portfolio
Figure 106: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 107: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 108: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 109: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 110: QIAGEN N.V.: SWOT Analysis
Figure 111: ST Pharm Co Ltd : Overall Product Portfolio
Figure 112: ST Pharm Co Ltd: SWOT Analysis
Figure 113: Sumitomo Chemical Co., Ltd.: Overall Product Portfolio
Figure 114: Sumitomo Chemical Co., Ltd: Overall Financials, 2018-2020
Figure 115: Sumitomo Chemical Co., Ltd.: Revenue (by Segment), 2018-2020
Figure 116: Sumitomo Chemical Co., Ltd: R&D Expenditure, 2018-2020
Figure 117: Sumitomo Chemical Co., Ltd.: SWOT Analysis
Figure 118: Syngene International Limited: Overall Product Portfolio
Figure 119: Syngene International Limited: Overall Financials, 2018-2020
Figure 120: Syngene International Limited: Revenue (by Region), 2018-2020
Figure 121: Syngene International Limited: R&D Expenditure, 2018-2020
Figure 122: Syngene International Limited: SWOT Analysis
Figure 123: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 124: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 125: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 127: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 128: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 129: Wuxi AppTec: Overall Product Portfolio
Figure 130: Wuxi AppTec: Overall Financials, 2018-2020
Figure 131: Wuxi AppTec: Revenue (by Segment), 2018-2020
Figure 132: Wuxi AppTec: Revenue (by Region), 2018-2020
Figure 133: Wuxi AppTec: R&D Expenditure, 2018-2020
Figure 134: Wuxi AppTec: SWOT Analysis
Figure 135: Yamasa Corporation: Overall Product Portfolio
Figure 136: Yamasa Corporation: SWOT Analysis
Figure 1: Global Nucleic Acid Therapeutics CDMO Market, Realistic and Optimistic Scenario, $Million
Figure 2: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
Figure 3: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 4: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company), 2019-2020
Figure 5: Global Nucleic Acid Therapeutics CDMO Market Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Global Nucleic Acid Therapeutics CDMO Market, $Million, 2020-2030
Figure 8: Optimistic View of Global Nucleic Acid Therapeutics CDMO Market, $Million
Figure 9: Overview of CRO and CDMO Services
Figure 10: Global Nucleic Acid Therapeutics CDMO Market, Market Dynamics
Figure 11: Deal Value of Mergers and Acquisitions Involving Cell and Gene Therapies (2016-2019)
Figure 12: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 13: Share of Mergers and Acquisitions (by Company), 2017-2021
Figure 14: Share of Synergistic Activities (by Company), 2017-2021
Figure 15: Market Share Analysis for Global Nucleic Acid Therapeutics CDMO Market, 2020
Figure 16: Growth Share Matrix for Global Nucleic Acid Therapeutics CDMO Market (by Company),2019- 2020
Figure 17: Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method)
Figure 18: Share of Global Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), 2020 and 2030
Figure 19: Solid-Phase Oligonucleotide Synthesis Market Size and Forecast
Figure 20: Liquid-Phase Oligonucleotide Synthesis Market Size and Forecast
Figure 21: Share of Global Nucleic Acid Therapeutics CDMO Market (by Technology), 2020 and 2030
Figure 22: Global Nucleic Acid Therapeutics CDMO Market (by Column-Based Method), 2020-2030
Figure 23: Global Nucleic Acid Therapeutics CDMO Market (by Microarray-Based Method), 2020-2030
Figure 24: Global Nucleic Acid Therapeutics CDMO Market, by End User, 2020 and 2030 ($Million)
Figure 25: Global Nucleic Acid Therapeutics CDMO Market, by Pharmaceutical and Biotechnology Companies
Figure 26: Global Nucleic Acid Therapeutics CDMO Market, by Academic Research Institutes
Figure 27: Global Nucleic Acid Therapeutics CDMO Market, by Diagnostic Laboratories
Figure 28: Global Nucleic Acid Therapeutics CDMO Market (by Product)
Figure 29: Share of Global Nucleic Acid Therapeutics CDMO Market (by Product), 2020 and 2030 ($Million)
Figure 30: Global Nucleic Acid Therapeutics CDMO Market, by Standard Nucleic Acid
Figure 31: Global Nucleic Acid Therapeutics CDMO Market, by Micro-Scale Nucleic Acid
Figure 32: Global Nucleic Acid Therapeutics CDMO Market, by Large-Scale Nucleic Acid Market
Figure 33: Global Nucleic Acid Therapeutics CDMO Market, by Custom Nucleic Acid
Figure 34: Global Nucleic Acid Therapeutics CDMO Market, by Modified Nucleic Acid
Figure 35: Global Nucleic Acid Therapeutics CDMO Market Primer Market, by Primers
Figure 36: Global Nucleic Acid Therapeutics CDMO Market, by Primer
Figure 37: Global Nucleic Acid Therapeutics CDMO Market, by Others NA
Figure 38: Global Nucleic Acid Therapeutics CDMO Market, Other Services
Figure 39: Global Nucleic Acid Therapeutics CDMO Market (by Region), Million Units, 2020-2030
Figure 40: Share of North America Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
Figure 41: North America: Market Dynamics
Figure 42: U.S. Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
Figure 43: Canada Nucleic Acid Therapeutics CDMO Market, 2020-2030, $Million
Figure 44: Share of Europe Nucleic Acid Therapeutics CDMO Market (by Country), 2020-2030, $Million
Figure 45: Europe: Market Dynamics
Figure 46: Germany Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 47: U.K. Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 48: France Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 49: Italy Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 50: Spain Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 51: Rest-of-Europe Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 52: APAC: Market Dynamics
Figure 53: Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (by Country), 2020-2030, $Million
Figure 54: China Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 55: India Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 56: Japan Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 57: Australia Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 58: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 59: Rest-of-the-World Nucleic Acid Therapeutics CDMO Market Revenue, 2020-2030, $Million
Figure 60: Shares of Key Company Profiles
Figure 61: Agilent Technologies, Inc.: Product Portfolio
Figure 62: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 63: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 64: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 65: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 66: Agilent Technologies, Inc.: SWOT Analysis
Figure 67: Ajinomoto Co. Inc,: Overall Product Portfolio
Figure 68: Ajinomoto Co., Inc.: Overall Financials, 2017-2019
Figure 69: Ajinomoto Co., Inc.: Revenue (by Segment), 2017-2019
Figure 70: Ajinomoto Co., Inc.: SWOT Analysis
Figure 71: Bachem Holding AG.: Overall Product Portfolio
Figure 72: Bachem Holding AG.: SWOT Analysis
Figure 73: Biospring GmbH: Overall Product Portfolio
Figure 74: Biospring GmbH: SWOT Analysis
Figure 75: Corden Pharma International: Overall Product Portfolio
Figure 76: Corden Pharma International: SWOT Analysis
Figure 77: Danaher Corporation: Product Portfolio
Figure 78: Danaher Corporation: Overall Financials, 2018-2020
Figure 79: Danaher Corporation: Revenue (by Segment), 2018-2020
Figure 80: Danaher Corporation: Revenue (by Region), 2018-2020
Figure 81: Danaher Corporation: R&D Expenditure, 2018-2020
Figure 82: Danaher Corporation: SWOT Analysis
Figure 83: Guangzhou Ruibo Biotechnology Co., Ltd.: Product Portfolio
Figure 84: Guangzhou Ruibo Biotechnology Co., Ltd: SWOT Analysis
Figure 85: KNC Laboratories Co., Ltd.: Overall Product Portfolio
Figure 86: KNC Laboratories Co., Ltd.: Overall Financials, 2018-2020
Figure 87: KNC Laboratories Co., Ltd.: SWOT Analysis
Figure 88: LGC Limited: Overall Product Portfolio
Figure 89: LGC Limited: Overall Financials, 2018-2020
Figure 90: LGC Limited: Revenue (by Segment), 2018-2020
Figure 91: LGC Limited: R&D Expenditure, 2018-2020
Figure 92: LGC Limited: SWOT Analysis
Figure 93: Merck KGaA: Product Portfolio
Figure 94: Merck KGaA: Overall Financials, 2018-2020
Figure 95: Merck KGaA: Revenue (by Segment), 2018-2020
Figure 96: Merck KGaA: Revenue (by Region), 2018-2020
Figure 97: Merck KGaA: R&D Expenditure, 2018-2020
Figure 98: Merck KGaA: SWOT Analysis
Figure 99: Nippon Shokubai Co., Ltd.: Overall Financials, 2018-2020
Figure 100: Nippon Shokubai Co., Ltd: Revenue (by Segment), 2018-2020
Figure 101: Nippon Shokubai Co., Ltd: R&D Expenditure, 2018-2020
Figure 102: Nippon Shokubai Co., Ltd: SWOT Analysis
Figure 103: Nitto Denko Avecia Inc.: Product Portfolio
Figure 104: Nitto Denko Avecia Inc.: SWOT Analysis
Figure 105: QIAGEN N.V.: Product Portfolio
Figure 106: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 107: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 108: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 109: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 110: QIAGEN N.V.: SWOT Analysis
Figure 111: ST Pharm Co Ltd : Overall Product Portfolio
Figure 112: ST Pharm Co Ltd: SWOT Analysis
Figure 113: Sumitomo Chemical Co., Ltd.: Overall Product Portfolio
Figure 114: Sumitomo Chemical Co., Ltd: Overall Financials, 2018-2020
Figure 115: Sumitomo Chemical Co., Ltd.: Revenue (by Segment), 2018-2020
Figure 116: Sumitomo Chemical Co., Ltd: R&D Expenditure, 2018-2020
Figure 117: Sumitomo Chemical Co., Ltd.: SWOT Analysis
Figure 118: Syngene International Limited: Overall Product Portfolio
Figure 119: Syngene International Limited: Overall Financials, 2018-2020
Figure 120: Syngene International Limited: Revenue (by Region), 2018-2020
Figure 121: Syngene International Limited: R&D Expenditure, 2018-2020
Figure 122: Syngene International Limited: SWOT Analysis
Figure 123: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 124: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 125: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 127: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 128: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 129: Wuxi AppTec: Overall Product Portfolio
Figure 130: Wuxi AppTec: Overall Financials, 2018-2020
Figure 131: Wuxi AppTec: Revenue (by Segment), 2018-2020
Figure 132: Wuxi AppTec: Revenue (by Region), 2018-2020
Figure 133: Wuxi AppTec: R&D Expenditure, 2018-2020
Figure 134: Wuxi AppTec: SWOT Analysis
Figure 135: Yamasa Corporation: Overall Product Portfolio
Figure 136: Yamasa Corporation: SWOT Analysis
LIST OF TABLES
Table 1: Oligonucleotide Therapies Approved by the FDA
Table 2: Nucleic Acid Therapies Approved by FDA and EMA
Table 3: Companies offering Standard Nucleic Acid
Table 4: Companies offering Micro-Scale Nucleic Acid
Table 5: Companies offering Large-Scale Nucleic Acid
Table 6: Companies offering Custom Nucleic Acid
Table 7: Companies offering Modified Nucleic Acid
Table 8: Companies offering Primers
Table 9: Companies offering Probes
Table 10: Companies offering Other NA
Table 11: Companies offering Other Services
Table 1: Oligonucleotide Therapies Approved by the FDA
Table 2: Nucleic Acid Therapies Approved by FDA and EMA
Table 3: Companies offering Standard Nucleic Acid
Table 4: Companies offering Micro-Scale Nucleic Acid
Table 5: Companies offering Large-Scale Nucleic Acid
Table 6: Companies offering Custom Nucleic Acid
Table 7: Companies offering Modified Nucleic Acid
Table 8: Companies offering Primers
Table 9: Companies offering Probes
Table 10: Companies offering Other NA
Table 11: Companies offering Other Services
